Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | NNMT | P40261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8432814 | 0.86 | NPSR1 (0.58) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| SCHEMBL16674216 | 0.85 | NPSR1 (0.65) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| Bromide SCHEMBL3051752 | 0.84 | NPSR1 (0.56) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| SCHEMBL10918992 | 0.83 | L3MBTL1 (0.63) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| SCHEMBL10220439 | 0.83 | APOBEC3A (0.50) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| SCHEMBL10307407 | 0.83 | KMT2A (0.53) | NPSR1L3MBTL1MAPTHSP90AA1KMT2A | |
| SCHEMBL5358005 | 0.83 | HSP90AA1 (0.58) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| SCHEMBL3630464 | 0.82 | MAPT (0.60) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| Bromide SCHEMBL3061420 | 0.82 | HSP90AA1 (0.60) | NPSR1L3MBTL1NNMTMAPTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL28336416 | 0.81 | KMT2A (0.52) | NPSR1L3MBTL1HSP90AA1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968013-B2 | Carbon nanotube N-doping material, carbon nanotube N-doping method and device using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-06-28 | — | — | US | disclosed |
| US-20100140561-A1 | CARBON NANOTUBE N-DOPING MATERIAL, CARBON NANOTUBE N-DOPING METHOD AND DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100140561-A1 | CARBON NANOTUBE N-DOPING MATERIAL, CARBON NANOTUBE N-DOPING METHOD AND DEVICE USING THE SAME | NNMT, NNT, NAMPT | NPSR1 1355/4885L3MBTL1 2356/4885NNMT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.